Recent Developments Not Encouraging
This Insight provides an update on developments in the US market related to biosimilars, and are of great significance to Celltrion Inc (068270...
322 Views
Eubiologics IPO Part 3 - IPO Bookbuilding Results & Personal View
Eubiologics IPO price was set at ₩6,000, the lowest end of the indicative price band, after conducting the demand survey (bookbuilding) (Jan 9-10)...
582 Views
Eubiologics IPO Part 2 - Growth Potential & Appropriate Valuation Level
*Â In Part 2 (as below), I examined the company's business fundamentals in more detail along with its growth potential and appropriate valuation...
325 Views
Eubiologics IPO Part 1 - Schedule, Financials & Valuation
Eubiologics is a very "young" vaccine company that develops an oral cholera vaccine product called "Euvichol". This company will be Korea's first...
487 Views
Korea Stock Market Monthly Recap #9 - (December 2016)
The economic hope post Trump win continued to play out in the global equity markets in December. Dow Jones Industrial Average was up 3.3% and...
556 Views